Doripenem: Difference between revisions
Gerald Chi (talk | contribs) mNo edit summary |
|||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Doripenem is an ultra-broad spectrum injectable [[antibiotic]]. It is a beta-lactam and belongs to the subgroup [[carbapenem]]. It was launched by[[Shionogi Co.]] of Japan under the [[brand name]] Finibax in 2005. It is particularly active against ''[[Pseudomonas aeruginosa]]''. | Doripenem is an ultra-broad spectrum injectable [[antibiotic]]. It is a beta-lactam and belongs to the subgroup [[carbapenem]]. It was launched by[[Shionogi Co.]] of Japan under the [[brand name]] Finibax in 2005. It is particularly active against ''[[Pseudomonas aeruginosa]]''. | ||
==Category== | ==Category== | ||
Carbapenem | Carbapenem | ||
==US Brand Names== | ==US Brand Names== | ||
DORIBAX<sup>®</sup> | DORIBAX<sup>®</sup> | ||
==FDA Package Insert== | ==FDA Package Insert== | ||
'''[[Doripenem description|Description]]''' | |||
''' [[Doripenem description|Description]]''' | |||
'''| [[Doripenem clinical pharmacology|Clinical Pharmacology]]''' | '''| [[Doripenem clinical pharmacology|Clinical Pharmacology]]''' | ||
'''| [[Doripenem microbiology|Microbiology]]''' | '''| [[Doripenem microbiology|Microbiology]]''' | ||
| Line 23: | Line 27: | ||
'''| [[Doripenem clinical studies|Clinical Studies]]''' | '''| [[Doripenem clinical studies|Clinical Studies]]''' | ||
'''| [[Doripenem dosage and administration|Dosage and Administration]]''' | '''| [[Doripenem dosage and administration|Dosage and Administration]]''' | ||
'''| [[Doripenem directions for use|Directions For Use]]''' | '''| [[Doripenem directions for use|Directions For Use]]''' | ||
'''| [[Doripenem how supplied|How Supplied]]''' | '''| [[Doripenem how supplied|How Supplied]]''' | ||
| Line 29: | Line 32: | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
Doripenem belongs to the [[carbapenem]] class of antimicrobials. Doripenem exerts its bactericidal activity by inhibiting bacterial cell wall biosynthesis. Doripenem inactivates multiple essential [[penicillin]] | |||
Doripenem belongs to the [[carbapenem]] class of antimicrobials. Doripenem exerts its bactericidal activity by inhibiting bacterial cell wall biosynthesis. Doripenem inactivates multiple essential [[penicillin-binding protein]]s (PBPs) resulting in inhibition of cell wall synthesis with subsequent cell death. In [[E. coli]] and [[P. aeruginosa]], [[doripenem binds]] to PBP 2, which is involved in the maintenance of cell shape, as well as to PBPs 3 and 4. | |||
==References== | ==References== | ||
Revision as of 22:04, 5 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Doripenem is an ultra-broad spectrum injectable antibiotic. It is a beta-lactam and belongs to the subgroup carbapenem. It was launched byShionogi Co. of Japan under the brand name Finibax in 2005. It is particularly active against Pseudomonas aeruginosa.
Category
Carbapenem
US Brand Names
DORIBAX®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | Directions For Use | How Supplied | Labels and Packages
Mechanism of Action
Doripenem belongs to the carbapenem class of antimicrobials. Doripenem exerts its bactericidal activity by inhibiting bacterial cell wall biosynthesis. Doripenem inactivates multiple essential penicillin-binding proteins (PBPs) resulting in inhibition of cell wall synthesis with subsequent cell death. In E. coli and P. aeruginosa, doripenem binds to PBP 2, which is involved in the maintenance of cell shape, as well as to PBPs 3 and 4.